Scientists at the University of Manchester (UK) have developed the first non-antibiotic drug to successfully treat tuberculosis (TB) in animal…
Browsing: Basic > Drug Development
From antibiotic susceptibility testing to new instruments to screen for antibiotics, 3D printing is contributing to research on antimicrobial resistance.
We take a look at the drugs that have been studied as treatments for confirmed prion diseases in humans – either in clinical trials, or on a compassionate, case-by-case basis – and look at what the future might hold for the treatment of prion diseases.
ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
Cerebral malaria is the most severe neurological complication of Plasmodium falciparum infection. Here, the authors discuss how NRG-1 could attenuate brain injury and mortality.
In this interview, take a look behind the scenes of a recent Future Microbiology paper on the role of transition metal control in E. coli virulence with author, Jeffrey Henderson.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.
Small-molecule compounds designed to tag the cell surface of Gram-negative bacteria and trigger an immunological response have shown promise.